EarningsQ2 2026 Earnings Report
DE:4PC Q2 2026 EPS Results
Actual EPS-€0.02
Consensus EPS-€0.02
Beat/MissMet expectations
One Year Ago EPS-€0.04
DE:4PC Q2 2026 Revenue Results
Actual Revenue€434.16K
Expected Revenue€595.06K
Beat/MissMissed by -€160.90K
YoY Revenue Growth-0.55%
Earnings Announcement Details
QuarterQ2 2026
Date08/20/2026
TimeAfter Close
Conference CallThursday, August 20, 2026
DE:4PC Upcoming Earnings
Perimeter Medical Imaging AI's next earnings date is estimated for November 17, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and operational inflection: meaningful sequential recurring revenue growth (+31% QoQ), significant cost reductions (OpEx down 28%), improvement in net loss (down 33%), reduced operating cash burn (down 23%), FDA PMA approval for the B-Series, two initial commercial B-Series placements now performing procedures, and a CMS filing in process. Counterbalancing this are the small absolute revenue base, ongoing losses and limited cash balance (~$6.4M), early-stage commercial scale (only two B-Series in the field), and timing uncertainty driven by evolving hospital AI/IT review processes and fluid pipeline visibility. Overall, the highlights outweigh the lowlights given the regulatory milestone, initial commercial traction and improving financial trends, but execution and cash management remain critical near-term risks.Company Guidance
Sequential Revenue Growth and Recurring Revenue
Recorded revenue of approximately $503k for Q2 2026, comprised fully of recurring revenue (S-Series consumables, system leases, preventative maintenance and ESP warranty programs). This represents ~31% sequential growth over Q1 2026.
Operating Expense Reduction
Quarterly operating expenses were $3.1M for Q2 2026, a 28% decrease versus $4.3M in Q2 2025, reflecting active cost-control measures.
Improved Net Loss
Net loss for Q2 2026 was $2.6M ( ~$0.02 per share), a 33% improvement from a $3.9M loss (~$0.04 per share) in Q2 2025.
Lower Operating Cash Burn and Cash Position
Cash used in operating activities for the six months ended June 30, 2026 was $5.1M, a 23% year-over-year decrease versus the comparable period in 2025. Cash on hand was $6.4M as of June 30, 2026 and management states the recent capital raise was intended to provide ~12 months runway.
Regulatory Milestone and Initial Commercial Deployments
Received FDA PMA approval for the next-generation AI-enabled B-Series device in April 2026. Since approval, the company completed two B-Series placements (conversions from S-Series) and both systems are installed and performing procedures; the company announced the first commercial hospital deployment.
Commercial Funnel Momentum and Reimbursement Progress
Management reports a growing sales funnel composed of legacy S-Series users (upgrade candidates) and net-new users; the company submitted a CMS HCPCS filing in June (currently under review), supporting future reimbursement efforts.
Positive Forward Outlook
Management forecasts material revenue acceleration into 2027 and remains bullish on growth trajectory. They indicated alignment with previously discussed targets (management expressed continued comfort with 2–3x revenue growth expectations, subject to timing of conversions).
DE:4PC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed